DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENALAPRILAT

« Back to Dashboard

All Clinical Trials for Enalaprilat

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00741156 ↗	The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution	Completed	The Hospital for Sick Children	Phase 3	2008-07-01	The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
NCT01324245 ↗	Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet	Completed	University of Virginia	N/A	2002-11-01	The kidney plays a crucial role in maintaining salt balance by two opposing physiological mechanisms: the renal dopaminergic system which enhances salt excretion and the renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension occurs when this balance is altered or abnormal. We hypothesized that this balance is influenced by salt intake: therefore dietary salt affects the natriuretic response to the renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor, Enalapril. In this trial we study normal salt balance mechanisms in salt resistant adults with normal blood pressure.
NCT01324245 ↗	Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet	Completed	Georgetown University	N/A	2002-11-01	The kidney plays a crucial role in maintaining salt balance by two opposing physiological mechanisms: the renal dopaminergic system which enhances salt excretion and the renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension occurs when this balance is altered or abnormal. We hypothesized that this balance is influenced by salt intake: therefore dietary salt affects the natriuretic response to the renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor, Enalapril. In this trial we study normal salt balance mechanisms in salt resistant adults with normal blood pressure.
NCT01413542 ↗	Pharmacogenetics of Ace Inhibitor-Associated Angioedema	Completed	Vanderbilt University	N/A	2011-11-01	The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.

Clinical Trial Conditions for Enalaprilat

Condition Name

Condition Name for Enalaprilat
Intervention	Trials
Heart Failure	3
Hypertension	2
Salt-sensitive Hypertension	1
Dilated Cardiomyopathy	1

Condition MeSH

Condition MeSH for Enalaprilat
Intervention	Trials
Hypertension	3
Heart Failure	3
Cardiomyopathy, Dilated	2
Cardiomyopathies	2

Clinical Trial Locations for Enalaprilat

Trials by Country

Trials by Country for Enalaprilat
Location	Trials
United States	2
Austria	2
Serbia	2
Netherlands	2
Hungary	2

Trials by US State

Trials by US State for Enalaprilat
Location	Trials
Tennessee	1
District of Columbia	1

Clinical Trial Progress for Enalaprilat

Clinical Trial Phase

Clinical Trial Phase for Enalaprilat
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Enalaprilat
Clinical Trial Phase	Trials
Completed	4
Not yet recruiting	3
Recruiting	1

Clinical Trial Sponsors for Enalaprilat

Sponsor Name

Sponsor Name for Enalaprilat
Sponsor	Trials
Ethicare GmbH	3
The George Institute	1
Georgetown University	1

Sponsor Type

Sponsor Type for Enalaprilat
Sponsor	Trials
Other	13
Industry	3